Cancers, Vol. 11, Pages 1381: BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

Cancers, Vol. 11, Pages 1381: BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale Cancers doi: 10.3390/cancers11091381 Authors: Jillian Wilhelmina Paulina Bracht Niki Karachaliou Trever Bivona Richard B. Lanman Iris Faull Rebecca J. Nagy Ana Drozdowskyj Jordi Berenguer Manuel Fernandez-Bruno Miguel Angel Molina-Vila Rafael Rosell BRAF V600 mutations have been found in 1–2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50–80% of BRAF mutations in lung cancer are non-V600, and can be class II, with intermediate to high kinase activity and RAS independence, or class III, with impaired kinase activity, upstream signaling dependence, and consequently, sensitivity to receptor tyrosine kinase (RTK) inhibitors. Plasma cell-free DNA (cfDNA) of 185 newly diagnosed advanced lung adenocarcinoma patients (Spanish Lung Liquid versus Invasive Biopsy Program, SLLIP, NCT03248089) was examined for BRAF and other alterations with a targeted cfDNA next-generation sequencing (NGS) assay (Guardant360®, Guardant Health Inc., CA, USA), and results were correlated with patient outcome. Cell viability with single or combined RAF, MEK, and SHP2 inhibitors was assessed in cell lines with BRAF class I, II, and III mu...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research

Related Links:

Conclusion: Data from our study suggest nivolumab is well-tolerated and effective in Indian patients with recurrent advanced NSCLC after failure of the multiple first lines of platinum-based combination chemotherapy.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality around the world. Brain metastasis (BM) is seen in up to 20-40% patients with NSCLC [1,2]. Patients with EGFR mutation have a higher likelihood of BM because of prolonged survival by EGFR tyrosine kinase inhibitors (EGFR-TKIs) [3 –5]. Further, whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) and surgical excision are options for local control, and each shows different treatment benefit in selected subgroups [6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In the palliative care of patients with non-small cell lung cancer (NSCLC), bronchial hypersecretion (bronchorrhea) may cause additional dyspnea and impaired quality of life. Bronchorrhea is defined as mostly aqueous sputum production with a volume of> 100ml / 24 hours. Various treatment options have been described in case reports and small series, including the use of tyrosine kinase inhibitors such as gefitinib and erlotinib, somatostatin analogues (octreotide), macrolide antibiotics, anti-inflammatory drugs (indomethacin, corticosteroids) and anticholinergics.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
This study aimed to investigate the feasibility of fitting dual-input tracer kinetic models to DCE-MRI datasets of thoracic malignancies, including malignant pleural mesothelioma (MPM) and nonsmall cell lung cancer (NSCLC), by comparing them to single-input (pulmonary or systemic arterial input) tracer kinetic models for the voxel-level analysis within the tumor with respect to goodness-of-fit statistics. Fifteen patients (five MPM, ten NSCLC) underwent DCE-MRI prior to radiotherapy. DCE-MRI data were analyzed using five different single- or dual-input tracer kinetic models: Tofts-Kety (TK), extended TK (ETK), two compartm...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
ConclusionsCollectively, these results implied that zunyimycin C could inhibit cell proliferation and induce apoptosis via AKT phosphorylation.
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Pemetrexed combined with platinum complexes can be used as first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC), however, the efficacy and safety is varying from individuals. There...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
Authors: Wu L, Zhang W, Qian J, Wu J, Jiang L, Ling C Abstract The R-spondin (RSPO) family of secreted proteins consists of four members that have critical roles in embryonic development and organogenesis. However, the expression patterns and the exact roles of the individual RSPO family members in tumorigenesis and progression of lung cancer are unknown, particularly in non-small cell lung cancer, which accounts for 85% of all lung cancer cases. In the present study, data from the ONCOMINE database was used to compare the RNA expression levels of RSPOs in multiple different types of cancer with normal controls. Th...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Jin C, Song P, Pang J Abstract Lung cancer negatively impacts global health, and the incidence of non-small cell lung cancer (NSCLC) is highest among all forms of lung cancer. Chemotherapy failure mainly occurs due to drug resistance; however, the associated molecular mechanism remains unclear. Casein kinase II (CK2), which plays important roles in the occurrence, development and metastasis of many tumours, regulates Wnt signaling by modulating β-catenin expression. In the present study the effects of the CK2 inhibitor, CX4945 on cisplatin [or cis-diamminedichloroplatinum (II); (DDP)]-resistant A549 c...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In 2007, the first anaplastic lymphoma kinase (ALK) fusion was described in non-small cell lung cancer (NSCLC)[1]. In 2013, a phase 3 study demonstrated a significant improvement in progression free survival (PFS) and overall survival (OS) in patients with metastasized ALK positive lung cancer treated with crizotinib compared to chemotherapy[2]. Subsequently, testing for ALK aberrations in patients with metastasized adenocarcinoma of the lung was recommended by international guidelines [3,4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsLAT and treatment beyond progression for oligo-progression after initial tumor response to anti-PD1 treatment provide encouraging survival outcomes in selected stage IV NSCLC patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureF. Guisier: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: MSD / Merck US; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (institution): Boehringer Ingelheim. R. Gervais: Honoraria (self), Advisory / Consultancy: AstraZenec...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Lung Cancer | Non-Small Cell Lung Cancer | Spain Health | Study